Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1205 participants.
Also called NCT07223593
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,205 participants
- Sponsor
- Registry
-
NCT07223593 -
2025-523283-21-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Brazil, Canada, China, France, Greece, India, Israel, Japan, Netherlands, Poland, Puerto Rico, Slovakia, South Korea, Taiwan, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07223593. Randomized; double masking; primary purpose treatment. Start 2025-10-31 (actual); primary completion 2028-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
- Acronym
- ATTAIN-PAD
- Condition
- Peripheral Arterial Disease
- Intervention (Drug)
- Orforglipron
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct07223593- Content hash
87cde6adb2337b49bc709f81ca8391f3f8b336fc1ab7ddac55ec3f4df4cacc28